Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914101 | 1.00 | MAPT (0.47) | MAPTTSHRMGAMGAASI | |
| SCHEMBL21835380 | 1.00 | MAPT (0.47) | MAPTTSHRMGAMGAASI | |
| SCHEMBL23913761 | 0.85 | TSHR (0.52) | MAPTTSHRMGAMGAASI | |
| SCHEMBL822244 | 0.84 | MAPT (0.55) | MAPTTSHRMGAMGAASI | |
| SCHEMBL822257 | 0.80 | MAPT (0.44) | MAPTTSHRMGAMGAASI | |
| SCHEMBL11880082 | 0.78 | MAPT (0.50) | MAPTTSHRMGAMGAASI | |
| SCHEMBL15826976 | 0.78 | MAPT (0.50) | MAPTTSHRMGAMGAASI | |
| SCHEMBL16411295 | 0.78 | MAPT (0.50) | MAPTTSHRMGAMGAASI | |
| SCHEMBL23913397 | 0.76 | TSHR (0.43) | MAPTTSHRMGAMGAASI | |
| SCHEMBL822223 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332432-B2 | Bioenergetically active esters for health and disease | UNIVERSITY OF KANSAS (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210317067-A1 | BIOENERGETICALLY ACTIVE ESTERS FOR HEALTH AND DISEASE | UNIVERSITY OF KANSAS | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332432-B2 | Bioenergetically active esters for health and disease | PC, ME2, CPT2 | MAPT 289/4885TSHR 4404/4885MGAM 747/4885 |
| US-20210317067-A1 | BIOENERGETICALLY ACTIVE ESTERS FOR HEALTH AND DISEASE | PC, ME2, CPT2 | MAPT 289/4885TSHR 4404/4885MGAM 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.